Press Releases

Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 4, 2016-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has elected to settle its conversion obligations in connection with any 1.625% Senior Convertible Notes due 2016 (the “Notes”) submitted for conversion on or after February 1, 2016 entirely in cash.

In accordance with the foregoing, Gilead notified Wells Fargo Bank, National Association, the Trustee for the Notes, that it had designated a “Cash Percentage” (as defined in the indenture governing the Notes (the “Indenture”)) of 100% to apply to the “Daily Share Amount” for every “Trading Day” during the relevant “Conversion Reference Period” (each as defined in the Indenture) applicable to the Notes.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936
Investor Relations